UK – NICE grants Lynparza expansion for advanced ovarian cancer

Lynparza (olaparib), the joint MSD and AstraZeneca cancer drug, has been granted an expansion by the National Institute for Health and Care Excellence (NICE) for maintenance treatment of certain cancers. The decision means that the PARP inhibitor is now the first and only of its kind in the UK to be approved in all lines of maintenance treatment.

The label extension now covers relapsed, platinum-sensitive high grade epithelial ovarian, fallopian tube or peritoneal cancer in adults whose disease has responded to platinum-based chemotherapy if they have a BRCA1 or BRCA2 mutation, meaning that the drug will be made available to patients within NHS England and Wales via routine commissioning if they have had three or more courses of platinum-based chemotherapy.

On top of this, it will be made available to patients within NHS England via the Cancer Drugs Fund (CDF) if they have had two courses of platinum-based chemotherapy…